slidedeck.co

Biotechnology decks.

5 decks from biotechnology companies, best reviewed first.

Cover slide of the Moderna 2026 investor presentation
Reporting decksReview score 8/10

Moderna investor presentation, Analyst Day 2026

The deck opens with a title slide and a forward-looking statement, followed by an introduction from CEO Stéphane Bancel.

Cover slide of the Moderna, Inc. 2026 investor presentation
Reporting decksReview score 7/10

Moderna, Inc. investor presentation, Third Quarter 2026 earnings call

The deck opens with a title slide and a forward-looking statements disclaimer, then an agenda naming the four speakers.

Cover slide of the Moderna 2026 investor presentation
Reporting decksReview score 7/10

Moderna investor presentation, Oncology Event, ESMO 2026

The deck opens with a cover for Moderna's oncology event dated October 2026, followed by standard forward-looking statements and an agenda listing speakers and key opinion leader perspectives.

Cover slide of the Aerbio 2024 investor presentation
Reporting decksReview score 7/10

Aerbio investor presentation, 2024

The deck opens with a title slide and then a page of investment disclaimers and representations that an investor must accept, followed by the company's one-line mission of turning carbon dioxide into protein with microbes.

Cover slide of the Capsida Biotherapeutics 2025 investor presentation
Reporting decksReview score 7/10

Capsida Biotherapeutics investor presentation, 2025

The deck opens with a title slide and a forward-looking statements disclaimer, then frames the problem with first-generation genetic medicines: poor blood-brain barrier crossing, liver and dorsal root ganglia toxicity, narrow therapeutic windows, and risky invasive routes of delivery.

Deck reviews in your inbox.

See what works in real company decks, what we’d change, and get the latest SDC releases.

Expanded slide preview